Homology Medicines (FIXX) Downgraded to “Sell” at Zacks Investment Research
Zacks Investment Research downgraded shares of Homology Medicines (NASDAQ:FIXX) from a hold rating to a sell rating in a report released on Thursday.
According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “
A number of other equities research analysts also recently weighed in on FIXX. ValuEngine downgraded Homology Medicines from a buy rating to a hold rating in a report on Friday, December 7th. Canaccord Genuity initiated coverage on Homology Medicines in a report on Monday. They issued a buy rating and a $37.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Homology Medicines has an average rating of Buy and an average price target of $27.75.
Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.03). The firm had revenue of $0.95 million during the quarter. Equities analysts predict that Homology Medicines will post -1.49 EPS for the current year.
In other news, Director Kush Parmar sold 15,575 shares of the business’s stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $26.01, for a total transaction of $405,105.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ventures Iv L.P. 5Am sold 525,900 shares of Homology Medicines stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $20.20, for a total value of $10,623,180.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 571,157 shares of company stock valued at $11,623,113.
Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new position in shares of Homology Medicines during the second quarter valued at approximately $558,000. BlackRock Inc. purchased a new position in shares of Homology Medicines during the second quarter valued at approximately $10,831,000. JPMorgan Chase & Co. boosted its position in shares of Homology Medicines by 29.7% during the third quarter. JPMorgan Chase & Co. now owns 2,251,444 shares of the company’s stock valued at $51,468,000 after buying an additional 516,156 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Homology Medicines during the second quarter valued at approximately $998,000. Finally, Global Thematic Partners LLC purchased a new position in shares of Homology Medicines during the third quarter valued at approximately $3,081,000. 53.41% of the stock is currently owned by institutional investors.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Further Reading: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.